Top Pharmacy Technician Pulse Dosage Insurance Content for Sun.Mar 13, 2022

Sun.Mar 13, 2022

AZ, Merck get FDA okay for Lynparza as adjuvant breast cancer therapy

pharmaphorum

MARCH 13, 2022

The FDA has cleared AstraZeneca and Merck & Co’s Lynparza as an adjuvant or neoadjuvant treatment for breast cancer, extending its lead over pretenders to its PARP inhibitor crown. The new approval is for use in patients with BRCA-mutated, HER2-negative early-stage breast cancer who have already been treated with chemotherapy – either before or after surgery – and are at high risk of the disease coming back.

FDA

FDA Chemotherapy Labelling

Biopharmaceutical Excipient Manufacturing – Current Scenario and Future Trends

Roots Analysis

MARCH 13, 2022

Over the years, the rising popularity of biologics has led to a paradigm shift in the healthcare industry. In the last decade alone, the annual number of approvals of biopharmaceuticals (including monoclonal antibodies, recombinant proteins, vaccines and gene therapies), by the US FDA, have steadily risen. In fact, over 8,000 biological pharmaceutical products are currently under clinical investigation worldwide.

Vaccines

Vaccines Compounding FDA

Sun.Mar 13, 2022

AZ, Merck get FDA okay for Lynparza as adjuvant breast cancer therapy

Biopharmaceutical Excipient Manufacturing – Current Scenario and Future Trends

Stay Connected